Zheng Wei, Zhang Pu, Yao Cenchao, Tao Yutao, Wang Zhida, Meng Shuai
Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Int J Neurosci. 2024 May 14:1-17. doi: 10.1080/00207454.2024.2356152.
In light of the increasing importance of immunotherapy in bladder cancer treatment, this study is aim to investigate the expression and clinical significance of programmed cell surface death-1 (PD-1) in bladder cancer patients without lymph node metastasis, and to compare and analyze the difference of PD-1 in draining lymph nodes and tumor tissues.
The expression of PD-1 on T cells and the proportion of positive PD-1 + T cells of IFN-γ and CD105a were detected by flow cytometry, and the correlation between PD-1 expression and clinical parameters was analyzed.
The percentage of PD-1 positive cells in drainage lymph nodes was higher than that in tumor tissues (P < 0.001). PD-1 positive cells accounted for the highest proportion in CD3 + T cells. The proportion of IFN-γ-positive PD-1 + T cells in draining lymph nodes was significantly higher than that in tumor tissues (P < 0.001), while there was no significant difference in CD105a positive PD-1 + T cells between tumor tissues and draining lymph nodes. Pathological grade, tumor size and stage were positively correlated with PD-1 expression level in the lymph nodes.
The high expression of PD-1 in patients with bladder cancer without lymph node metastasis, especially in draining lymph nodes, suggests that PD-1 may play a key role in the regulation of tumor immune microenvironment. The correlation between PD-1 and clinical parameters indicates its potential prognostic value. These findings provide important clinical implications for PD-1 targeted therapy, but further prospective studies are needed to determine the application value of PD-1 in therapeutic strategies.
鉴于免疫治疗在膀胱癌治疗中日益重要，本研究旨在探讨程序性细胞表面死亡-1（PD-1）在无淋巴结转移的膀胱癌患者中的表达及临床意义，并比较分析引流淋巴结与肿瘤组织中PD-1的差异。
采用流式细胞术检测T细胞上PD-1的表达以及IFN-γ和CD105a的PD-1+T细胞阳性比例，并分析PD-1表达与临床参数之间的相关性。
引流淋巴结中PD-1阳性细胞百分比高于肿瘤组织（P<0.001）。PD-1阳性细胞在CD3+T细胞中占比最高。引流淋巴结中IFN-γ阳性的PD-1+T细胞比例显著高于肿瘤组织（P<0.001），而肿瘤组织与引流淋巴结中CD105a阳性的PD-1+T细胞无显著差异。病理分级、肿瘤大小和分期与淋巴结中PD-1表达水平呈正相关。
无淋巴结转移的膀胱癌患者中PD-1高表达，尤其是在引流淋巴结中，提示PD-1可能在肿瘤免疫微环境调节中起关键作用。PD-1与临床参数之间的相关性表明其潜在的预后价值。这些发现为PD-1靶向治疗提供了重要的临床启示，但需要进一步的前瞻性研究来确定PD-1在治疗策略中的应用价值。
